GIANT BIOGENE (02367) Publishes Monthly Return for February 2026

Bulletin Express03-04

GIANT BIOGENE (stock code: 02367) released its monthly return for the period ended 28 February 2026. According to the document, the authorized share capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001 each, totaling USD 50,000. The number of issued shares was unchanged from the preceding month at 1.07 billion, and there were no treasury shares throughout the period.

The company's public float requirement was confirmed as being met. Under the 2023 Share Option Scheme, 11.60 million share options outstanding at the close of the preceding month dropped to zero by the end of February, with no new shares issued and no treasury shares transferred. The filing also shows that 9.20 million shares had been repurchased previously for cancellation but remained not yet cancelled as of 13 June 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1149769535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 17:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149769535","market":"hk","top_or_hot":-1,"title":"GIANT BIOGENE (02367) Publishes Monthly Return for February 2026","media":"Bulletin Express","content":"<p>GIANT BIOGENE (stock code: 02367) released its monthly return for the period ended 28 February 2026. According to the document, the authorized share capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001 each, totaling USD 50,000. The number of issued shares was unchanged from the preceding month at 1.07 billion, and there were no treasury shares throughout the period.</p>\n<p>The company's public float requirement was confirmed as being met. Under the 2023 Share Option Scheme, 11.60 million share options outstanding at the close of the preceding month dropped to zero by the end of February, with no new shares issued and no treasury shares transferred. The filing also shows that 9.20 million shares had been repurchased previously for cancellation but remained not yet cancelled as of 13 June 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GIANT BIOGENE (02367) Publishes Monthly Return for February 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGIANT BIOGENE (02367) Publishes Monthly Return for February 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-04 17:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GIANT BIOGENE (stock code: 02367) released its monthly return for the period ended 28 February 2026. According to the document, the authorized share capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001 each, totaling USD 50,000. The number of issued shares was unchanged from the preceding month at 1.07 billion, and there were no treasury shares throughout the period.</p>\n<p>The company's public float requirement was confirmed as being met. Under the 2023 Share Option Scheme, 11.60 million share options outstanding at the close of the preceding month dropped to zero by the end of February, with no new shares issued and no treasury shares transferred. The filing also shows that 9.20 million shares had been repurchased previously for cancellation but remained not yet cancelled as of 13 June 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"","article_id":"1149769535","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149769535","pubTimestamp":1772617741,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"GIANT BIOGENE (stock code: 02367) released its monthly return for the period ended 28 February 2026. According to the document, the authorized share capital remained at 5.00 billion ordinary shares...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02367":"巨子生物"},"translate_title":"巨人生物基因(02367)公布2026年2月月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1},"content_text":"GIANT BIOGENE (stock code: 02367) released its monthly return for the period ended 28 February 2026. According to the document, the authorized share capital remained at 5.00 billion ordinary shares with a par value of USD 0.00001 each, totaling USD 50,000. The number of issued shares was unchanged from the preceding month at 1.07 billion, and there were no treasury shares throughout the period.\nThe company's public float requirement was confirmed as being met. Under the 2023 Share Option Scheme, 11.60 million share options outstanding at the close of the preceding month dropped to zero by the end of February, with no new shares issued and no treasury shares transferred. The filing also shows that 9.20 million shares had been repurchased previously for cancellation but remained not yet cancelled as of 13 June 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1149769535","isCrawlerRequest":true}